Clinical Trials Logo

Lymphangioleiomyomatosis (LAM) clinical trials

View clinical trials related to Lymphangioleiomyomatosis (LAM).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04388371 Completed - Clinical trials for Lymphangioleiomyomatosis (LAM)

Glutamine PET Imaging in LAM

Start date: October 18, 2019
Phase: Phase 1
Study type: Interventional

In this study, subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such as sirolimus or everolimus to undergo a PET/CT scan using an novel PET tracer that may better evaluate disease activity in LAM subjects both before and after the initiation of mTOR inhibitor therapy will be enrolled. The procedure for each scan will be similar, involving one administration of the novel tracer C11-glutamine followed by a whole body PET/CT scan.

NCT ID: NCT02484664 Completed - Clinical trials for Lymphangioleiomyomatosis (LAM)

COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

COLA
Start date: June 15, 2016
Phase: Phase 2
Study type: Interventional

The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site). The Specific Aims are: Aim 1: To investigate whether, in LAM patients, celecoxib is safe and well tolerated, and has evidence of clinical benefit. Aim 2: To investigate the potential value of a novel biomarker of LAM, quantitative measurement of the number of TSC2 mutant LAM cells per ml of blood, to assess disease severity.

NCT ID: NCT00790400 Completed - Clinical trials for Lymphangioleiomyomatosis (LAM)

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

EXIST-2
Start date: April 2009
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.